Zynlonta

Zynlonta (loncastuximab tesirine) is an intravenous therapy for relapsed or refractory large B-cell lymphoma. This CD19-directed antibody and alkylating agent targets cancer cells. It is prescribed when prior treatments have not succeeded. Always consult a healthcare provider for suitability.

Zynlonta is used to treat adults with relapsed or refractory large B-cell lymphoma after at least two prior therapies. It targets CD19-positive cancer cells, helping to slow disease progression. This medication is typically considered when standard treatments have not been effective. It is administered under medical supervision in clinical settings.

Zynlonta works by binding to cancer cells and delivering a cytotoxic agent to reduce tumor size. Patients may experience changes in blood cell counts due to its effects on rapidly dividing cells. Regular monitoring is recommended to track response and manage potential changes in health status.

Zynlonta is given by healthcare professionals in a controlled environment due to its potent effects. Patients should report any new or worsening symptoms, including infections or unusual bleeding. Avoid close contact with individuals who are sick during treatment. Keep all scheduled appointments for blood tests and evaluations.

Drug interactions with Zynlonta are not fully established, but caution is advised with other medications that affect the immune system or blood cell counts. Alcohol and certain supplements may increase side effects. Always inform your provider about all medications and supplements being taken before starting treatment.